Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles : synergistic cytotoxicity in brain tumour cells
The aims of this study were to develop co-delivery systems of paclitaxel (PTX) and etoposide prodrug (4'-O-benzyloxycarbonyl-etoposide, ETP-cbz) based on non-cross-linked human serum albumin (HSA) and poly(lactide-co-glycolide) nanoparticles and to evaluate the synergistic potential of these drugs in vitro. The nanoformulations were prepared by the high-pressure homogenisation technique and characterised using DLS, TEM, SEM, AFM, HPLC, CZE, in-vitro release, and cytotoxicity in human and murine glioma cells. All nanoparticles had 90-150 nm in size and negative ζ-potentials. The Neuro2A cells were the most sensitive to both HSA- and PLGA-based co-delivery systems (IC50 0.024 µM and 0.053 µM, respectively). The drugs' synergistic effect (combination index < 0.9) was observed in the GL261 cells for both types of co-delivery formulations and in the Neuro2A cells for the HSA-based system. These nanodelivery systems may be useful to improve combination chemotherapy for brain tumour treatment. To our knowledge, this is the first report describing the non-cross-linked HSA-based co-delivery nanosuspension which was prepared using nab™ technology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 40(2023), 4 vom: 16. Juni, Seite 246-262 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kovshova, Tatyana [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.05.2023 Date Revised 15.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02652048.2023.2188943 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353862789 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353862789 | ||
| 003 | DE-627 | ||
| 005 | 20231226061002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2023.2188943 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353862789 | ||
| 035 | |a (NLM)36880479 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kovshova, Tatyana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles |b synergistic cytotoxicity in brain tumour cells |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2023 | ||
| 500 | |a Date Revised 15.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The aims of this study were to develop co-delivery systems of paclitaxel (PTX) and etoposide prodrug (4'-O-benzyloxycarbonyl-etoposide, ETP-cbz) based on non-cross-linked human serum albumin (HSA) and poly(lactide-co-glycolide) nanoparticles and to evaluate the synergistic potential of these drugs in vitro. The nanoformulations were prepared by the high-pressure homogenisation technique and characterised using DLS, TEM, SEM, AFM, HPLC, CZE, in-vitro release, and cytotoxicity in human and murine glioma cells. All nanoparticles had 90-150 nm in size and negative ζ-potentials. The Neuro2A cells were the most sensitive to both HSA- and PLGA-based co-delivery systems (IC50 0.024 µM and 0.053 µM, respectively). The drugs' synergistic effect (combination index < 0.9) was observed in the GL261 cells for both types of co-delivery formulations and in the Neuro2A cells for the HSA-based system. These nanodelivery systems may be useful to improve combination chemotherapy for brain tumour treatment. To our knowledge, this is the first report describing the non-cross-linked HSA-based co-delivery nanosuspension which was prepared using nab™ technology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Co-delivery | |
| 650 | 4 | |a GL261 glioma cells | |
| 650 | 4 | |a HSA nanoparticles | |
| 650 | 4 | |a Neuro-2a neuroblastoma cells | |
| 650 | 4 | |a PLGA nanoparticles | |
| 650 | 4 | |a etoposide pro-drug | |
| 650 | 4 | |a paclitaxel | |
| 650 | 4 | |a synergistic effect | |
| 650 | 4 | |a сytotoxicity | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 650 | 7 | |a Prodrugs |2 NLM | |
| 650 | 7 | |a Serum Albumin, Human |2 NLM | |
| 650 | 7 | |a ZIF514RVZR |2 NLM | |
| 700 | 1 | |a Mantrov, Sergey |e verfasserin |4 aut | |
| 700 | 1 | |a Boiko, Svetlana |e verfasserin |4 aut | |
| 700 | 1 | |a Malinovskaya, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Merkulova, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Osipova, Nadezhda |e verfasserin |4 aut | |
| 700 | 1 | |a Moiseeva, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Akimov, Mikhail |e verfasserin |4 aut | |
| 700 | 1 | |a Dudina, Polina |e verfasserin |4 aut | |
| 700 | 1 | |a Senchikhin, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Ermolenko, Yulia |e verfasserin |4 aut | |
| 700 | 1 | |a Gelperina, Svetlana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g 40(2023), 4 vom: 16. Juni, Seite 246-262 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:4 |g day:16 |g month:06 |g pages:246-262 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2023.2188943 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 4 |b 16 |c 06 |h 246-262 | ||